The technology doesn't offer enough of a difference to the current process with the time saved only for 1 out of the 6 manual assessments. This limitation has always been the biggest issue for me, if only the facial assessment was required then the uptake will be a lot more easier to sell the technology especially globally as they don't need to know the APS manual process. There won't be any difference in what PCK is currently encountered while trying to commercialise globally right now even after FDA approval and then trying to commercialise into the US market, I would be very surprise if a US healthcare company don't see this limitation.
PCK Price at posting:
3.0¢ Sentiment: None Disclosure: Not Held
